---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-012813"
form_type: "8-K"
ticker: null
cik: "0001591165"
company_name: "Innoveren Scientific, Inc."
filed_at: "2023-04-18T23:59:59+00:00"
generated_at: "2026-06-17T00:44:17.137152+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# H-CYTE raises $135,000 in convertible note offering with warrants

## Summary
- Sold $135,000 of 8% convertible promissory notes to three investors under SPA.
- Notes convertible at 20% discount to qualified offering price; $100k matures 1 year or qualified closing, $35k matures 60 days.
- Warrants for 20% of conversion shares at $2.00 exercise price, 5-year term.
- Part of up to $1M offering; further closings through April 30, 2023 (extendable to June 30).
- Issued under Section 4(a)(2) and Rule 506(b) exemption.

## SEC filing metadata
- accession: 0001493152-23-012813
- form_type: 8-K
- cik: 0001591165
- company_name: Innoveren Scientific, Inc.
- filed_at: 2023-04-18T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1591165/000149315223012813/0001493152-23-012813-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1591165/000149315223012813/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-012813
- JSON: https://secwatch.observer/filing/0001493152-23-012813.json
- Plain text: https://secwatch.observer/filing/0001493152-23-012813.txt

## Key facts
- Debt Financings
  Innoveren Scientific, Inc. incurred convertible notes of $135,000 with three investors at 8% per annum maturing earlier of (i) one year from issuance; or (ii) upon the closing of a qualified offering.
  - Instrument: convertible notes
  - Principal: $135,000
  - Counterparty: three investors
  - Rate: 8% per annum
  - Maturity: earlier of (i) one year from issuance; or (ii) upon the closing of a qualified offering
  - Event: incurrence
  source text: On April 12, 2023, H-Cyte, Inc., (the “Company”) and three investors entered into a Securities Purchase Agreement (the “SPA”), whereby, the Company sold and issued to the certain investors, an aggregate of one hundred thirty five thousand dollars ($135,000.00) of the Company’s convertible promissory notes
  evidence_url: https://www.sec.gov/Archives/edgar/data/1591165/000149315223012813/0001493152-23-012813-index.htm
- Material Agreements
  Innoveren Scientific, Inc. entered into Securities Purchase Agreement with three investors valued at $135,000.00 (effective 2023-04-12).
  - Action: entry
  - Agreement: notes offering
  - Counterparty: three investors
  - Value: $135,000.00
  - Effective: 2023-04-12
  source text: On April 12, 2023, H-Cyte, Inc., (the “Company”) and three investors entered into a Securities Purchase Agreement (the “SPA”), whereby, the Company sold and issued to the certain investors, an aggregate of one hundred thirty five thousand dollars ($135,000.00) of the Company’s convertible promissory notes
  evidence_url: https://www.sec.gov/Archives/edgar/data/1591165/000149315223012813/0001493152-23-012813-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.